Elitek (Rasburicase) Immuno-Monitoring Study
NCT01097369 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2013-01-31
Summary
Primary Objective:
To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hypersensitivity reaction or loss of uricolytic activity.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Sciences & Operations · Sanofi
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-02-28
- Primary Completion
- 2010-02-28
- Completion
- 2010-02-28
Countries
- United States
Study Locations
More Related Trials
-
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
NCT02848001 ·Status: TERMINATED ·Phase: PHASE1
-
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
NCT05316116 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
SAR3419 in Acute Lymphoblastic Leukemia
NCT01440179 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
NCT02742090 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
NCT06708897 ·Status: RECRUITING ·Phase: PHASE1
-
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
NCT02848911 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT02503033 ·Status: UNKNOWN ·Phase: PHASE1
-
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
NCT00759603 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT04155580 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
NCT01147939 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
NCT01522469 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
NCT05537766 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00481091 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
NCT00320190 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
NCT01035216 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT03734016 ·Status: COMPLETED ·Phase: PHASE3
-
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
NCT06281847 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
NCT00522990 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
NCT02530619 ·Status: UNKNOWN ·Phase: NA
-
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
NCT02484430 ·Status: COMPLETED ·Phase: PHASE2
-
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
NCT03194893 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
NCT01328626 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT03206918 ·Status: COMPLETED ·Phase: PHASE2
-
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
NCT04125290 ·Status: TERMINATED
-
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT02046928 ·Status: TERMINATED ·Phase: PHASE2